The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori
Sponsor: Seoul National University Bundang Hospital
A observational or N/A phase clinical study on Helicobacter Infection, this trial is actively recruiting participants. The trial is conducted by Seoul National University Bundang Hospital and has accumulated 13 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Study Description(click to expand)As increasing antimicrobial resistance in Korea, the effectiveness of empirical Helicobacter pylori (H. pylori) therapies have been declined. Recently, 10-day sequential therapy was not sufficient to overcome tough situation for H. pylori eradication.
Thus, in this study, the investigators evaluated the efficacy of H. pylori eradication between a 7 days tailored therapy (7 day PPI based triple therapy, bismuth quadruple therapy or moxifloxacin contained triple therapy) for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the 10 day sequential therapy for the first eradication of H. pylori infection, and the investigators analyzed the prevalence of the antibiotic resistance in the tailored therapy group.
As increasing antimicrobial resistance in Korea, the effectiveness of empirical Helicobacter pylori (H. pylori) therapies have been declined. Recently, 10-day sequential therapy was not sufficient to overcome tough situation for H. pylori eradication.
Thus, in this study, the investigators evaluated the efficacy of H. pylori eradication between a 7 days tailored therapy (7 day PPI based triple therapy, bismuth quadruple therapy or moxifloxacin contained triple therapy) for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the 10 day sequential therapy for the first eradication of H. pylori infection, and the investigators analyzed the prevalence of the antibiotic resistance in the tailored therapy group.
Status Flow
Change History
13 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Status: Unknown → Recruiting · Phase: NA → None
-
Sep 2025 — Apr 2026 [monthly]
Unknown NA
-
May 2025 — Sep 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 8 earlier versions
-
May 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Apr 2023 — May 2023 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Apr 2021 — Apr 2023 [monthly]
Recruiting NA
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
May 2019 — Jan 2021 [monthly]
Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Recruiting NA
-
Jan 2018 — Jun 2018 [monthly]
Recruiting NA
Status: Enrolling By Invitation → Recruiting
-
Jan 2017 — Jan 2018 [monthly]
Enrolling By Invitation NA
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
Contact Information
- Seoul National University Bundang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .